CD8A and Sepsis: To determine the immune cell subset(s) that impact sepsis survival in the context of CD28-agonist treatment in immunologically-experienced septic mice, depleting antibodies against CD25, CD4, or CD8 (or control PBS) were administered before and after CLP in mice receiving anti-CD28 injections (Figure 1A).